Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent for its investigative cannabinoid-derived drug candidate anabasum to treat multiple fibrotic diseases. Issued by the U.S. Patent and Trademark Office, the mark gives Corbus protection in the United States until 2034. It adds to a patent…
News
University of Colorado researchers have discovered a molecule that prevents the activation of a receptor that scientists believe is involved in autoimmune diseases. The team at university’s BioFrontiers Institute used the compound to block the receptor’s action. Their work may alter the path of therapy development in scleroderma and other…
The National Organization for Rare Disorders (NORD) says it’s “disappointed and dismayed” after the House of Representatives voted 227-205 last week to repeal the Orphan Drug Tax Credit as part of a U.S. tax reform package. A similar package before the Senate Finance Committee does not repeal the credit…
Scleroderma patients’ nerve-related hand problems, including numbness, tingling and pain, may stem from the main nerve to the hands becoming stiffer than normal, according to Turkish researchers. The team discovered that the nerve was stiffer than usual at both the wrist and forearm. This prompted them to suggest that scientists…
A study of the gut bacterial composition in scleroderma patients identified unique bacterial alterations associated with clinical evidence of gastrointestinal disease. Many patients with scleroderma, also known as systemic sclerosis (SSc), suffer from gastrointestinal tract symptoms, with almost all of those with longstanding disease having upper gastrointestinal involvement. Focus has recently shifted…
Non-invasive Shock Wave Therapy Speeds Healing of Digital Ulcers in Systemic Sclerosis, Study Shows
Non-invasive extracorporeal shock wave therapy (ESWT) was shown to significantly improve the wound healing process in patients with systemic sclerosis and digital ulcers. Results from the study, presented at the 2017 ACR/ARHP Annual Meeting in San Diego, suggest that ESWT can be safely used as a therapeutic option to…
75% of Scleroderma Patients Show Meaningful Skin Improvement with Anabasum, Extension Study Shows
The thick skin that is a hallmark of scleroderma showed meaningful improvement in 75 percent of patients treated with Corbus Pharmaceuticals’ anabasum (JBT-101), according to initial results of an extension trial. Corbus discussed the first six months’ findings of the one-year extension study at the American College of Rheumatology Annual Meeting in San…
Corbus Pharmaceuticals is sharing a host of data on anabasum (JBT-101) for the treatment of diffuse cutaneous scleroderma at the ongoing American College of Rheumatology (“ACR”) 2017 Annual Meeting in San Diego. Researchers presented data from an earlier Phase 2 trial of the cannabinoid-derived drug, along with a study proving…
Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent fo its investigative cannabinoid-derived drug candidate anabasum to treat inflammatory diseases. The new patent (No. 9,801,849), issued by the U.S. Patent and Trademark Office, protects the use of anabasum for the treatment of systemic sclerosis, dermatomyositis,…
Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with the National Organization for Rare Disorders (NORD) to become the first of many U.S. “centers of excellence” to look after patients with rare diseases, regardless of age. The effort…
Recent Posts
- Cell therapy linked to skin improvements in scleroderma trial
- Scleroderma patients open to aesthetic treatments, survey finds
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track